buthionine sulfoximine

Small moleculeexperimental

Buthionine sulfoximine (BSO) is a sulfoximine derivative which reduces levels of glutathione and is being investigated as an adjunct with chemotherapy in the treatment of cancer. The compound inhibits gamma-glutamylcysteine synthetase, the enzyme required in the first step of glutathione synthesis. Buthionine sulfoximine may also be used to increase the sensitivity of parasites to oxidative antiparasitic drugs. — Wikipedia

Clinical trial activity

3 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Jun 1, 1996 (NCT00002730)

Timeline

1990s

  1. Jan 1, 1996

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCCCS(=N)(=O)CCC(N)C(=O)O
Mol. weight
222.31 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • buthionine sulfoximine
  • buthionine sulfoximine
  • buthionine sulfoximine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00661336Phase 1Apr 1, 2008Duke University, National Cancer Institute (NCI)
NCT00005835Phase 1Aug 1, 2001National Cancer Institute (NCI), University of Chicago
NCT00002730Phase 1Jun 1, 1996National Cancer Institute (NCI), University of Southern California
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government3111996
Duke UniversityAcademic/Hospital1112008
University of ChicagoAcademic/Hospital1012001
University of Southern CaliforniaAcademic/Hospital1111996
4 organizations
Page 1 / 1